PDF(Pubmed)
Abstract：
UNASSIGNED: Sarcoidosis is a chronic inflammatory disorder of unknown etiology associated with high morbidity and mortality. Its association with cardiovascular outcomes is under-documented.
UNASSIGNED: The aim of this study was to assess the adverse cardiovascular outcomes in patients with sarcoidosis compared with that of non-sarcoidosis.
UNASSIGNED: Online databases including PubMed, Embase and Scopus were queried from inception until March 2022. The outcomes assessed included all-cause mortality (ACM) and incidence of ventricular tachycardia (VT), heart failure (HF) and atrial arrhythmias (AA).
UNASSIGNED: A total of 6 studies with 22,539,096 participants (42,763 Sarcoidosis, 22,496,354 Non-Sarcoidosis) were included in this analysis. The pooled prevalence of sarcoidosis was 13.1% (95% CI 1% to 70%). The overall mean age was 47 years. The most common comorbidities were hypertension (12.7% vs 12.5%), and diabetes mellitus (5.5% vs 4%) respectively. The pooled analysis of primary endpoints showed that all-cause mortality (RR, 2.08; 95% CI: 1.17 to 3.08; p = 0.01) was significantly increased in sarcoidosis patients. The pooled analysis of secondary endpoints showed that the incidence of VT (RR, 15.3; 95% CI: 5.39 to 43.42); p < 0.001), HF (RR, 4.96; 95% CI: 2.02 to 12.14; p < 0.001) and AA (RR, 2.55; 95% CI: 1.47 to 4.44); p = 0.01) were significantly higher with sarcoidosis respectively compared to non-sarcoidosis.
UNASSIGNED: Incidence of VT, HF and AA was significantly higher in patients with CS. Clinicians should be aware of these adverse cardiovascular events associated with sarcoidosis.
UNASSIGNED: The aim of this study was to assess the adverse cardiovascular outcomes in patients with sarcoidosis compared with that of non-sarcoidosis.
UNASSIGNED: Online databases including PubMed, Embase and Scopus were queried from inception until March 2022. The outcomes assessed included all-cause mortality (ACM) and incidence of ventricular tachycardia (VT), heart failure (HF) and atrial arrhythmias (AA).
UNASSIGNED: A total of 6 studies with 22,539,096 participants (42,763 Sarcoidosis, 22,496,354 Non-Sarcoidosis) were included in this analysis. The pooled prevalence of sarcoidosis was 13.1% (95% CI 1% to 70%). The overall mean age was 47 years. The most common comorbidities were hypertension (12.7% vs 12.5%), and diabetes mellitus (5.5% vs 4%) respectively. The pooled analysis of primary endpoints showed that all-cause mortality (RR, 2.08; 95% CI: 1.17 to 3.08; p = 0.01) was significantly increased in sarcoidosis patients. The pooled analysis of secondary endpoints showed that the incidence of VT (RR, 15.3; 95% CI: 5.39 to 43.42); p < 0.001), HF (RR, 4.96; 95% CI: 2.02 to 12.14; p < 0.001) and AA (RR, 2.55; 95% CI: 1.47 to 4.44); p = 0.01) were significantly higher with sarcoidosis respectively compared to non-sarcoidosis.
UNASSIGNED: Incidence of VT, HF and AA was significantly higher in patients with CS. Clinicians should be aware of these adverse cardiovascular events associated with sarcoidosis.
摘要：
■结节病是一种病因不明的慢性炎症性疾病，与高发病率和死亡率相关。其与心血管结局的关联记录不足。
■本研究的目的是评估结节病与非结节病患者的心血管不良结局。
■在线数据库，包括PubMed，Embase和Scopus从成立到2022年3月都受到了质疑。评估的结果包括全因死亡率（ACM）和室性心动过速（VT）的发生率，心力衰竭（HF）和房性心律失常（AA）。
■共有6项研究，有22,539,096名参与者（42,763例结节病，此分析包括22,496,354非结节病）。结节病的合并患病率为13.1％（95％CI1％至70％）。总体平均年龄为47岁。最常见的合并症是高血压（12.7%vs12.5%），和糖尿病（分别为5.5％和4％）。主要终点的汇总分析表明，全因死亡率(RR，2.08；95%CI：1.17~3.08；p=0.01）在结节病患者中显著升高。次要终点的汇总分析表明，VT的发生率(RR，15.3；95%CI：5.39至43.42）；p<0.001），HF(RR,4.96；95%CI：2.02至12.14；p<0.001）和AA（RR，2.55；95％CI：1.47至4.44）；p=0.01）与结节病相比，结节病分别显着高于非结节病。
■室性心动过速的发生率，CS患者中HF和AA显著增高。临床医生应该意识到这些与结节病相关的不良心血管事件。
■本研究的目的是评估结节病与非结节病患者的心血管不良结局。
■在线数据库，包括PubMed，Embase和Scopus从成立到2022年3月都受到了质疑。评估的结果包括全因死亡率（ACM）和室性心动过速（VT）的发生率，心力衰竭（HF）和房性心律失常（AA）。
■共有6项研究，有22,539,096名参与者（42,763例结节病，此分析包括22,496,354非结节病）。结节病的合并患病率为13.1％（95％CI1％至70％）。总体平均年龄为47岁。最常见的合并症是高血压（12.7%vs12.5%），和糖尿病（分别为5.5％和4％）。主要终点的汇总分析表明，全因死亡率(RR，2.08；95%CI：1.17~3.08；p=0.01）在结节病患者中显著升高。次要终点的汇总分析表明，VT的发生率(RR，15.3；95%CI：5.39至43.42）；p<0.001），HF(RR,4.96；95%CI：2.02至12.14；p<0.001）和AA（RR，2.55；95％CI：1.47至4.44）；p=0.01）与结节病相比，结节病分别显着高于非结节病。
■室性心动过速的发生率，CS患者中HF和AA显著增高。临床医生应该意识到这些与结节病相关的不良心血管事件。
